Alzheimer Therapeutics Market Size, Share and Trends 2025 to 2034

Leading players are expanding their reach in personalized medicines and targeting therapies for cutting-edge Alzheimer's therapeutics. North America, Asia Pacific, Latin America, and Europe are seeking spectacular expansion with the rising geriatric population, prevalence of disease, and improvements in healthcare infrastructure.

Pharmaceutical companies like Roche, Bristol Myers Squibb, Sanofi, Novartis AG, Eisai Co., Ltd, AbbVie Inc., and Biogen Inc. are the major investors in Alzheimer therapeutic discovery and drug developments. Furthermore, venture capital funds, including the Dementia Discovery Fund (DDF), are investing more than $550 million to support innovative treatments for Alzheimer’s.

In 2024, the mild to moderate Alzheimer’s disease segment dominated the market, with a share of 46.7 0%, due to increased use of cholinesterase inhibitors like Rivastigmine, Galantamine, and Donepezil for the treatment of patients with mild to moderate Alzheimer’s disease. The increased prevalence of Alzheimer’s disease requires a well-established efficacy to manage symptoms. The majority of patients are diagnosed with mild to moderate Alzheimer’s disease, creating large patient pools, driving the need for both existing treatments like cholinesterase inhibitors and novel, high-cost options. Researchers are focusing on developing and testing drugs for mild to moderate Alzheimer’s disease stages with high-cost treatment options, leading to a boost in focus on enhancing accessibility and economic sustainability.

The mild cognitive impairment (MCI) Due to Alzheimer’s segment is expected to grow fastest with a 11.20% CAGR from 2025 to 2034, due to increased prevalence in the elderly population. The mild cognitive impairment (MCI) is creating opportunities to target disease-modifying therapies (DMTs) like donanemab and lecanemab. These therapies help to slow cognitive declines. The growing focus on strategies for slowing disease progression and management of modifiable risk factors is fueling innovation in mild cognitive impairment (MCI). Additionally, the ongoing development of novel therapies like anti-amyloid drugs and their approvals to use in mild cognitive impairment (MCI) patients are contributing to the segment’s growth.

In 2024, the oral segment dominated the market, with a share of 61.30%, due to its convenient nature and cost-effectiveness. The oral administration is practical, secure, and straightforward for both caregivers and patients. The wide availability of oral medications like NMDA receptor antagonists and cholinesterase inhibitors is fueling the segment’s growth. Patients prefer oral administration due to lower healthcare costs, fewer needs for hospital visits, and the market availability and accessibility of numerous oral drug options. The ongoing approvals for oral drugs like benzgalantamine are further supporting the market.

The intravenous (IV) segment is expected to lead the market, over the forecast period, with a 10.60% CAGR, due to growing approvals for novel disease-modifying monoclonal antibody (mAb) treatments, like donanemab and lecanemab. The intravenous (IV) route of administration enhances efficacy and sustained therapeutic effects. The intravenous (IV) has been effective in slowing disease progression, reducing amyloid beta plaques, and slowing cognitive decline. The increasing demand for disease-modifying therapies is fueling innovations and the development of intravenous (IV) medications. Additionally, the ongoing research and development of therapies like next-generation immunotherapies and alternative infusion routes are fostering the expansion of the segment in the upcoming period.

The hospital pharmacy segment dominated the market, with a share of 44.90% in 2024, due to its strategic role in patient care. Hospital pharmacies have high prescription rates and a significant role in integrated care. The growing number of hospitalizations of Alzheimer’s patients is contributing to this growth. The centralized procurements and need for sophisticated and coordinated care drive patient preference for hospital pharmacies. The ongoing access to novel and complex treatment solutions and medications like disease-modifying drugs drives the need for qualified medical professionals. Hospital pharmacies offer direct relationships with pharmaceutical companies, facilitating timely treatments.

The online pharmacy segment is growing fastest at an 11.80% CAGR over the forecast period, driven by increased adoption of digital platforms and patient convenience. The online pharmacy provides convenient delivery of medications. The widespread internet access and the accelerated shift in behavior due to the COVID-19 pandemic have boosted patient preference for online purchase of medicines. Additionally, the online pharmacies are cost-effective compared to hospital and retail pharmacies, as they can offer competitive pricing and discounts. The rising shift toward home deliveries is fueling the segment’s growth.

Asia Pacific is the fastest-growing region in the global market, with an expected growth of 10.90% CAGR from 2025 to 2034, driven by the rising geriatric population and government initiatives. Expanding healthcare infrastructure and investments in R&D are fueling innovations and developments of novel treatments, like tau aggregation inhibitors (TAIs) for slowing Alzheimer’s disease. Asia has experienced a large growth in awareness of neurodegenerative disease. The Alzheimer’s Disease International (ADI) organization is involved in sustainable support from the government in regional developments and impacting on national dementia plans, particularly in Malaysia and the Maldives. The expanding online pharmaceuticals and government-supported activities to manage disease in Asia are solidifying its position in the global market.

China’s Innovative Approaches to Fuel Alzheimer Therapeutics Market Growth

China is a major player in the regional market due to the expanding healthcare infrastructure, the rising aging population, and the growing prevalence of disease in the country. More than 16 million people in China have been affected by Alzheimer’s. China has introduced a national action plan for combating dementia by 2030. The continuous development of novel treatments and the official approval of lecanemab are further adding to this growth. The strong pharmaceutical focus on disease-modifying therapies and utilization of biomarkers in drug development are maturing China’s market.

Clinical trials and regulatory approvals of Alzheimer’s therapeutics are conducted in a multi-stage process, heavily regulated by frameworks such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Key Players: Eli Lilly & Company, Biogen, Johnson & Johnson, and Roche.

Pharmaceutical companies secure regulatory approvals for novel medications with dedicated support programs, assisting with treatment adherence and access.

Key Players: Eisai, ACR Data, Cognito Therapeutics, and Biogen.